个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Huang Dingzhi[1] * ; Lin Gen[2] * ; Chu Qian[3] * ; Hu Yi[4] * ; Wang Jun[5] * ; Wang Zhijie[6] * ; Yang Fan[7] * ; Zhong Wenzhao[8] * ; Zhou Chengzhi[9] * ; Zhu Bo[10] * ; Ai Xinghao[11] ; Cao Baoshan[12] ; Cao Yabing[13] ; Chen Mingqiu[14] ; Chen Xiaohui[15] ; Chu Tianqing[16] ; Duan Jianchun[6] ; Fan Yun[17] ; Fang Yong[18] ; Feng Shuitu[19] ; Feng Weineng[20] ; Guo Hui[21] ; Han Chengbo[22] ; He Yong[23] ; Hong Shaodong[24] ; Hu Jie[25] ; Huang Meijuan[26] ; Huang Yan[24] ; Jiang Da[27] ; Jiang Kan[2] ; Jiang Richeng[1] ; Jin Bo[28] ; Jin Shi[29] ; Li Jisheng[30] ; Li Min[31] ; Li Ziming[11] ; Li Chao[32] ; Lin Jie[33] ; Liu Anwen[34] ; Liu Si-Yang Maggie[35] ; Liu Yutao[6] ; Liu Zhefeng[4] ; Liu Zhe[36] ; Liu Zhenhua[37] ; Liu Zhentian[38] ; Liu Zhigang[39] ; Lu Yuping[40] ; Lv Tangfeng[41] ; Ma Zhiyong[42] ; Miao Qian[2] ; Peng Min[43] ; Pu Xingxiang[44] ; Ren Xiu Bao[45] ; Shan Jianzhen[46] ; Shan Jinlu[47] ; Shen Peng[48] ; Shen Bo[49] ; Shi Meiqi[49] ; Song Yong[41] ; Song Zhengbo[50] ; Su ChunXia[51] ; Sun Jianguo[10] ; Tian Panwen[52] ; Wang Jinliang[4] ; Wang Feng[15] ; Wang Huijuan[42] ; Wang Jialei[53] ; Wang Qian[54] ; Wang Wenxian[17] ; Wang Yan[6] ; Wu Lin[44] ; Wu Fang[55] ; Xia Yang[56] ; Xie Congying[57] ; Xie Conghua[58] ; Xin Tao[59] ; Xiong Jianping[60] ; Xu Haipeng[2] ; Xu Song[61] ; Xu Yiquan[2] ; Xu Bin[43] ; Xu Chunwei[41] ; Yan Xiaolong[62] ; Yang Zhenzhou[63] ; Yao Wenxiu[64] ; Yu Yao[21] ; Feng Ye[65] ; Yu Zongyang[66] ; Yu Yongfeng[11] ; Yue Dongsheng[67] ; Zhang Haibo[68] ; Zhang HongMei[69] ; Zhang Li[3] ; Zhang Longfeng[2] ; Zhang Qiuyu[70] ; Zhang Tongmei[36] ; Zhang Bicheng[43] ; Zhao Jun[71] ; Zhao Mingfang[28] ; Zheng Xiaobin[2] ; Zhong Fengqiao[2] ; Zhou Jin[64] ; Zhou Penghui[24] ; Zhu Zhengfei[72] ; Zou Juntao[73] ; Zou Zihua[2] ;
机构： [1]Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China. [2]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. [3]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China. [4]Senior Department of Oncology, Chinese PLA General Hospital, Beijing, People's Republic of China. [5]Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Ji'nan, People's Republic of China. [6]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. [7]Department of Thoracic Surgery, Peking University People Hospital, Beijing, People's Republic of China. [8]Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. [9]Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China. [10]Institute of Cancer, Xinqiao Hospital, Army Medical University, Chongqing, People's Republic of China. [11]Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. [12]Cancer center, Peking University Third Hospital/ Department of medical oncology and radiation sickness, Peking University Third Hospital, Beijing, People's Republic of China. [13]Department of oncology, Kiang Wu Hospital, Macau, People's Republic of China. [14]Department of Thoracic Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. [15]Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. [16]Respiratory Department, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. [17]Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China. [18]Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhenjiang University School of Medicine, Hangzhou, People's Republic of China. [19]Department of Medical Oncology, Fudan University Shanghai Cancer Center Xiamen Hospital, Xiamen, People's Republic of China. [20]Department of Pulmonary Oncology, The First People's Hospital of Foshan, Foshan, People's Republic of China. [21]Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China. [22]Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China. [23]Department of Respiratory Medicine, Xinqiao Hospital, Army Medical University, Chongqing, People's Republic of China. [24]State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. [25]Zhongshan Hospital, Fudan University, Shanghai Geriatric Center, Shanghai, People's Republic of China. [26]Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China. [27]Department of Oncology, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China. [28]Department of Medical Oncology, The First affiliated hospital of China Medical University, Shenyang, People's Republic of China. [29]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital &Shenzhen Hospital, Chinese Academy of Medical Sciences and Perking Union Medical College, Shenzhen, People's Republic of China. [30]Department of Medical Oncology, Qilu Hospital of Shandong University, Ji'nan, People's Republic of China. [31]Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, People's Republic of China. [32]Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. [33]Department of Medical Oncology, The Second Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China. [34]Department of Medical Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China. [35]Department of Hematology, First Affiliated Hospital, Ji'nan University, Guangzhou, People's Republic of China. [36]Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China. [37]Department of Oncology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, People's Republic of China. [38]Department of Thoracic Oncology,Jiangxi Cancer Hospital, Nanchang, People's Republic of China. [39]Cancer Center, The 10th Affiliated Hospital of Southern Medical University, Dongguan, People's Republic of China. [40]Department of Abdominal Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. [41]Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, People's Republic of China. [42]Department of Respiratory Medicine, Henan Cancer Hospital /Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, People's Republic of China. [43]Cancer center, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China. [44]Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China. [45]Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China. [46]Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Zhejiang, People's Republic of China. [47]Department of Medical Oncology, Daping Hospital, Army Medical University, Chongqing, People's Republic of China. [48]Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China. [49]Department of Medical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, People's Republic of China. [50]Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China. [51]Department of Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, People's Republic of China. [52]Department of Pulmonary and Critical Care Medicine, Lung Cancer Center, West China Hospital, Sichuan University, Precision Medicine Key Laboratory of Sichuan Province, Chengdu, People's Republic of China. [53]Department of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China. [54]Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, People's Republic of China. [55]Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, People's Republic of China. [56]Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, People's Republic of China. [57]Department of Radiation and Medical Oncology, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China. [58]Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. [59]Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China. [60]Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China. [61]Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, People's Republic of China. [62]Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, People's Republic of China. [63]Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China. [64]Department of Medical Oncology, Sichuan Cancer Hospital, University of Electronic Science and Technology of China, Chengdu, People's Republic of China. [65]Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, People's Republic of China. [66]Department of Respiratory Medicine, The 900th Hospital of the Joint Logistic Support Force, People's Liberation Army of China, Fuzhou, People's Republic of China. [67]Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China. [68]Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, People's Republic of China. [69]Department of Clinical Oncology, Xijing Hospital, Air Force Medical University, Xi'an, People's Republic of China. [70]Institute of Immunotherapy, Fujian Medical University, Fuzhou, People's Republic of China. [71]Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, People's Republic of China. [72]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China. [73]Department of Respiratory Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China.
出处：
DOI： 10.1111/1759-7714.15157
ISSN：

关键词： immunotherapy NSCLC secondary resistance

摘要：
Immune checkpoint inhibitors (PD-1/PD-L1 and CTLA-4 blockade) have revolutionized the treatment landscape in non-small cell lung cancer (NSCLC). Secondary resistance to immunotherapy (IO), which poses a substantial challenge in clinical settings, occurs in several initial responders. Currently, new treatment approaches have been extensively evaluated in investigational studies for these patients to tackle this difficult problem; however, the lack of consistency in clinical definition, uniform criteria for enrollment in clinical trials, and interpretation of results remain significant hurdles to progress. Thus, our expert panel comprehensively synthesized data from current studies to propose a practical clinical definition of secondary resistance to immunotherapy in NSCLC in metastatic and neoadjuvant settings. In addition to patients who received IO alone (including IO-IO combinations), we also generated a definition for patients treated with chemotherapy plus IO. This consensus aimed to provide guidance for clinical trial design and facilitate future discussions with investigators. It should be noted that additional updates in this consensus are required when new data is available.© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 3 区 医学
小类 | 4 区 肿瘤学 4 区 呼吸系统
最新[2023]版：
大类 | 3 区 医学
小类 | 4 区 肿瘤学 4 区 呼吸系统
JCR分区：
出版当年[2023]版：
Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY
最新[2023]版：
Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Huang Dingzhi,Lin Gen,Chu Qian,et al.Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer[J].THORACIC CANCER.2023,14(34):3421-3429.doi:10.1111/1759-7714.15157.
APA：
Huang Dingzhi,Lin Gen,Chu Qian,Hu Yi,Wang Jun...&Zou Zihua.(2023).Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer.THORACIC CANCER,14,(34)
MLA：
Huang Dingzhi,et al."Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer".THORACIC CANCER 14..34(2023):3421-3429

相关文献

[1]Blockading a new NSCLC immunosuppressive target by pluripotent autologous tumor vaccines magnifies sequential immunotherapy [2]Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms [3]中、晚期非小细胞肺癌144例用CAP、EP、IP三方案化疗疗效、毒性比较 [4]Application of combined ablation and immunotherapy in NSCLC and liver cancer: Current status and future prospects [5]EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis [6]High HPK1+PD-1+TIM-3+CD8+ T cells infiltration predicts poor prognosis to immunotherapy in NSCLC patients [7]Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview [8]Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC [9]Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study [10]Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

资源点击量：52808 今日访问量：2 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号